Prime Minister Lee Hsien Loong spoke about Singapore’s new initiatives to attract and retain top talent to secure Singapore’s success in a post-COVID-19 world. Specific to talent in Singapore’s biomedical sector, PM Lee mentioned that home-grown scientists are now doing cutting-edge research and development, with some who have become principal researchers and others who have founded start-ups.

MiRXES is proud and humbled to be featured in the NDR 2022. We have grown from a three-man team in 2014 to over 360 staff across offices in Singapore, US, China, Japan, and several Southeast Asian countries. We have been a beneficiary of many government initiatives in talent development, technology innovation, internationalization, and scale-up, that have enabled us to develop talent and translate RNA innovation from bench to bedside, and we look forward to continue contributing to Singapore’s vibrant biotechnology ecosystem and Healthier SG initiative.

MiRXES announced today that it has launched Project CADENCE (CAncer Detected Early caN be CurEd), the world’s first large-scale clinical research project for the discovery and validation of novel combinations blood-borne circulating microRNA (miRNA) and DNA methylation biomarkers that will lead to the development of a multi-cancer early detection test for up to nine high incidence and high mortality cancers.

MiRXES has opened the first industry 4.0 (i4.0) in vitro diagnostic (IVD) manufacturing facility in Southeast Asia. This S$8 million facility at JTC MedTech Hub is the largest i4.0 IVD manufacturing site at in Southeast Asia at 15,000 square feet.

MiRXES announced today that Dr. Lihan ZHOU, Co-founder and Chief Executive Officer at MiRXES, Dr. Ruiyang ZOU, Co-founder and Chief Technology Officer at MiRXES and Mr. Isaac HO, Chief Investment Officer at MiRXES, have been named EY Entrepreneur Of The Year (EOY) 2021 Singapore by professional services organization, EY.

At-home cancer tests that could detect the disease even in the absence of symptoms? They could very well be a possibility in the future.

Dr Zhou is the Chief Executive Officer of MiRXES, a biotechnology company he co-founded with Chief Technology Officer Dr Zou Ruiyang, that specialises in producing polymerase chain reaction (PCR) tests to detect early stage cancer. The company brings to life his vision, running with the ethos that prevention is better than cure, and that early detection enables early interception, leading to early treatment and subsequently, saved and improved lives.